QT
STLN

Quantbot Technologies’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Quantbot Technologies’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29K Buy
+9,455
New +$29K ﹤0.01% 1468
2025
Q4 		– Sell
-4,926
Closed -$17.2K – 2172
2025
Q3 		$17.2K Buy
+4,926
New +$16.9K ﹤0.01% 1610

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Quantbot Technologies's STLN Position: Q1 2026 in Review

Quantbot Technologies opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2026: 9,455 shares worth $29K. The stake represents ﹤0.01% of the portfolio and ranks #1468 among its holdings. This is a return to the name: Quantbot Technologies previously reported a position in STLN as recently as Q3 2025.

Quantbot Technologies first reported a position in STLN in Q3 2025 and has held it in 2 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Quantbot Technologies held 9,455 shares of Starling Oncology Institute, Inc. Common Stock worth $29K as of Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock was a new Quantbot Technologies position in Q1 2026.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Quantbot Technologies's portfolio in Q1 2026, its #1468 holding.
  • Quantbot Technologies first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2025 and has held it in 2 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Quantbot Technologies's 13F filing for Q1 2026, filed 13 May 2026.